Back to search

Article

Glutaredoxin 3 (GLRX3) confers a fusion oncogene-dependent vulnerability to Ewing sarcoma

2024-04-26

Abstract excerpt

<h4>ABSTRACT</h4> Ewing sarcoma (EwS) is a highly aggressive bone and soft-tissue associated cancer for which there are no effective targeted therapeutics available. Genetically, EwS is driven by aberrantly active EWSR1::ETS fusion transcription factors, most commonly EWSR1::FLI1. Despite their unique expression in EwS, all attempts to effectively target these fusion oncoproteins clinically were not yet successfu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b99f72e5-333a-5303-8919-3d0d35094b2d
DOI
10.1101/2024.04.24.590877
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Glutaredoxin 3 (GLRX3) confers a fusion oncogene-dependent vulnerability to Ewing sarcomaDOI 10.1101/2024.04.24.590877
Select a neighboring publication to make it the new centre.